(EMAILWIRE.COM, October 01, 2019 ) The factors expected to drive the growth of the market are rising need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine offer significant growth opportunities in the HCS market. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the HCS market.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

High Content Screening Market is segmented into following types:

* Based on product, the global market is broadly segmented into instruments, consumables, software, services, and accessories. Among all high content screening products, instrument segment caters to the largest share. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=42710391

Some of The Major Players High Content Screening Market :

1. GE Healthcare (U.S.)
2. Danaher Corporation (U.S.)
3. Thermo Fisher Scientific, Inc. (U.S.)
4. PerkinElmer, Inc. (U.S.)
5. Tecan Group (Switzerland)
6. BioTek Instruments Inc. (U.S.)

Get Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=42710391

The global high content screening market is projected to reach USD 909.0 million by 2022 from USD 557.1 million in 2017 at a CAGR of 10.3% from 2017 to 2022. The need for cost containment in pharma R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.